MyMigraineTeam

Both Qulipta (atogepant) and Ubrelvy (ubrogepant) are CGRP medications that work in different but complementary ways. Qulipta is specifically designed for migraine prevention and is taken once daily. Studies show it can reduce monthly migraine days by 3-4 days on average, which could be significant for someone experiencing Show Full Answer

Both Qulipta (atogepant) and Ubrelvy (ubrogepant) are CGRP medications that work in different but complementary ways. Qulipta is specifically designed for migraine prevention and is taken once daily. Studies show it can reduce monthly migraine days by 3-4 days on average, which could be significant for someone experiencing 4-6 migraines monthly. Ubrelvy is designed for acute treatment when a migraine attack occurs. It works quickly to block CGRP and relieve symptoms without causing extreme drowsiness. Many people experience relief within two hours, and if needed, a second dose can be taken within 24 hours if symptoms persist. Common side effects for both medications may include fatigue, upset stomach, and dry mouth. For best results with acute treatments like Ubrelvy, take them as early as possible when you notice migraine symptoms beginning. This allows the medication to be fully absorbed and reach peak effectiveness when you need it most.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Migraine Treatments: Medications, Devices, Anti-CGRP Drugs, and More (VIDEO)

Anti-CGRP Medications for Migraine: Atogepant, Eptinezumab, and More